moomoo ID:NaN
Log Out
Log in to access Online Inquiry

Magnus Financial Group LLC Lowers Stake in Aprea Therapeutics, Inc. (NASDAQ:APRE)

Financial News Live ·  {{timeTz}}

Magnus Financial Group LLC lessened its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) by 56.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,856 shares of the company's stock after selling 19,125 shares during the quarter. Magnus Financial Group LLC's holdings in Aprea Therapeutics were worth $28,000 at the end of the most recent quarter.

Separately, PDT Partners LLC lifted its holdings in shares of Aprea Therapeutics by 62.5% in the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the period. 18.95% of the stock is owned by institutional investors and hedge funds.

Get Aprea Therapeutics alerts:

Analyst Upgrades and Downgrades

Separately, Wedbush started coverage on Aprea Therapeutics in a research note on Thursday, July 7th. They set an "outperform" rating and a $3.00 price target on the stock.

Aprea Therapeutics Stock Performance

NASDAQ APRE opened at $0.78 on Friday. The company has a market cap of $18.25 million, a PE ratio of -0.14 and a beta of 0.63. The firm's 50 day moving average price is $0.93 and its 200-day moving average price is $1.24. Aprea Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $5.67.

About Aprea Therapeutics

(Get Rating)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Read More

  • Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?

Want to see what other hedge funds are holding APRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating).

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.